Establishing the novel ex-vivo focal demyelination model of Multiple Sclerosis in other laboratories to reduce and replace live animal use.

在其他实验室建立新型多发性硬化症离体局灶性脱髓鞘模型,以减少和替代活体动物的使用。

基本信息

  • 批准号:
    NC/W000989/1
  • 负责人:
  • 金额:
    $ 9.5万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2021
  • 资助国家:
    英国
  • 起止时间:
    2021 至 无数据
  • 项目状态:
    已结题

项目摘要

Current therapies for treating multiple sclerosis (MS) patients are inadequate for managing progressive MS, so new therapies are needed. The central nervous system of MS patients has some areas that seem relatively unaffected (the neuronal fibres retain their insulating sheath called myelin), whereas other areas are damaged (the myelin is lost, compromising neuronal function and health). This is a dynamic situation, whereby the body continually repairs the damage, but ultimately fails with disease progression. Much research aims to enhance remyelination (repairing the myelin sheath) as a key area for new therapeutic intervention, thus protecting the health and function of the neurons. However, to test new remyelination based therapies, laboratory animals must be used to model MS, and these models are costly, often don't faithfully replicate the "patchy" nature of the human disease, and shed limited light on how the therapy worked.We have recently made a better laboratory model of MS, that allows this patchy nature of MS demyelination to be recapitulated in a dish, without using live animals in the process. Researchers can now, for the first time, study the complex interplay between the "healthy" and "damaged" tissue in a dish. This advancement means that new remyelination therapies can be tested faster, more effectively, with better understanding of how they are working, and greatly reduces the number of animals required.Where previously one live adult animal would give one experimental result for one region of their nervous system (i.e., either the brain or spinal cord), our new model uses slices of euthanised newborn mouse brain or spinal cord cultured in dishes and analysed separately. This gives researchers six brain slices AND 10 spinal cord slices - all from a single animal. Where 100s of lab animals would be used for a single therapeutic test, now the tissue of a few animals can be used instead, with the added benefit of better understanding how the therapy works too. It is also important to mention that previously an experimental animal may have had to experience suffering during the interventions required to create the MS condition, whereas no intervention is carried out on a live animal with this new model that we have developed, thus replacing the use of live animals.Having seen the power of this model to increase scientific value and reduce the use of animals, we are now keen to transfer these skills and knowledge to other research groups working on MS. Dr. Dombrowski and Prof. Fitzgerald, both running independent research groups at Queen's University Belfast, approached us to use this model in their laboratories. This grant has three aims. Firstly, to finance a researcher to bring the skills and knowledge associated with the new MS model to the Belfast laboratories. The primary aim is to reduce the number of animals needed in their research, by replacing their existing live animal models with our new model. Secondly, we aim to encourage widespread adoption of this model throughout the UK, Europe and elsewhere, by making training videos and detailed protocols freely available online, thus leading to better MS research capabilities with lower animal use. Lastly, we will optimise the production of the materials required to make this new MS model, so that it can easily be rolled out to large number of laboratories in a simple, cost-effective and reproducible manner. We foresee that the immediate and tangible benefits that this new model of MS will bring to researchers will be a major attraction driving them to adopt it. These include reduced costs (live animal experiments are costly), the ability to work on multiple nervous system regions concomitantly and gaining better insight into how the therapeutic is working. This grant is required to catalyse and drive this adoption, spreading the knowledge and protocols required for this model, reducing animal use worldwide.
目前治疗多发性硬化症患者的方法不足以治疗进展性多发性硬化症,因此需要新的治疗方法。多发性硬化症患者的中枢神经系统有一些区域似乎相对不受影响(神经纤维保留了被称为髓鞘的绝缘鞘),而其他区域受到了损害(髓鞘丢失,损害了神经元的功能和健康)。这是一种动态的情况,身体不断修复损伤,但最终随着疾病的发展而失败。许多研究旨在加强髓鞘再生(修复髓鞘),作为新的治疗干预的关键领域,从而保护神经元的健康和功能。然而,为了测试基于重新髓鞘形成的新疗法,必须使用实验室动物来模拟多发性硬化症,这些模型成本高昂,通常不能忠实地复制人类疾病的“斑块”性质,而且对治疗如何起作用的解释也有限。我们最近制作了一个更好的多发性硬化症实验室模型,它允许在培养皿中重现多发性硬化症的这种斑片状脱髓鞘性质,而不需要在这个过程中使用活动物。研究人员现在可以首次研究盘子中“健康”和“受损”组织之间的复杂相互作用。这一进步意味着,新的再髓鞘疗法可以更快、更有效地进行测试,更好地了解它们是如何工作的,并大大减少所需动物的数量。以前,一只活的成年动物只能对其神经系统的一个区域(即大脑或脊髓)给出一个实验结果,而我们的新模型使用在培养皿中培养的安乐死新生小鼠大脑或脊髓的切片,并分别进行分析。这为研究人员提供了6个脑片和10个脊髓片--所有这些都来自一只动物。在一个单一的治疗测试中,将使用100只实验室动物,现在可以替代使用几个动物的组织,另外一个好处是更好地了解这种疗法是如何起作用的。同样值得一提的是,以前实验动物可能不得不经历造成多发性硬化症的干预过程中的痛苦,而我们开发的这种新模型不会对活体动物进行干预,从而取代了对活体动物的使用。在看到这种模型在增加科学价值和减少动物使用方面的力量后,我们现在热衷于将这些技能和知识转移到其他研究小组,他们都是贝尔法斯特女王大学的独立研究小组的负责人,他们与我们接洽,希望在他们的实验室使用这个模型。这笔赠款有三个目标。首先,资助一名研究人员将与新的MS模型相关的技能和知识带到贝尔法斯特的实验室。主要目的是通过用我们的新模型取代他们现有的活体动物模型,减少他们研究中所需的动物数量。其次,我们的目标是通过在网上免费提供培训视频和详细的方案,鼓励在英国、欧洲和其他地方广泛采用这种模式,从而以较少的动物使用量带来更好的多发性硬化症研究能力。最后,我们将优化制造这种新的MS模型所需的材料的生产,以便它能够以简单、成本效益高和可重复的方式轻松地推广到大量实验室。我们预计,这种新的多发性硬化症模型将给研究人员带来直接和切实的好处,这将是推动他们采用它的主要吸引力。这些包括降低成本(活体动物实验成本很高),同时在多个神经系统区域工作的能力,以及更好地了解治疗是如何起作用的。需要这笔赠款来催化和推动这种采用,传播这种模式所需的知识和方案,减少全球范围内的动物使用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ben Newland其他文献

A reliable method for detecting complexed DNA in vitro.
体外检测复合 DNA 的可靠方法。
  • DOI:
    10.1039/c0nr00456a
  • 发表时间:
    2010
  • 期刊:
  • 影响因子:
    6.7
  • 作者:
    C. Holladay;Michael Keeney;Ben Newland;Asha Mathew;Wenxin Wang;A. Pandit
  • 通讯作者:
    A. Pandit
Catechol functionalized hyperbranched polymers as biomedical materials
  • DOI:
    https://doi.org/10.1016/j.progpolymsci.2017.09.002
  • 发表时间:
    2018
  • 期刊:
  • 影响因子:
  • 作者:
    Hong Zhang;Tianyu Zhao;Ben Newland;Wenguang Liu;Wei Wang;Wenxin Wang
  • 通讯作者:
    Wenxin Wang
Complex polymer architectures through free-radical polymerization of multivinyl monomers
通过多乙烯基单体的自由基聚合形成复杂的聚合物结构
  • DOI:
    10.1038/s41570-020-0170-7
  • 发表时间:
    2020-03-23
  • 期刊:
  • 影响因子:
    51.700
  • 作者:
    Yongsheng Gao;Dezhong Zhou;Jing Lyu;Sigen A;Qian Xu;Ben Newland;Krzysztof Matyjaszewski;Hongyun Tai;Wenxin Wang
  • 通讯作者:
    Wenxin Wang

Ben Newland的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ben Newland', 18)}}的其他基金

Rethinking repurposing: Developing cryogel technology to address glioblastoma recurrence through year-long local delivery of repurposed therapeutics
重新思考重新利用:开发冷冻凝胶技术,通过为期一年的局部重新利用治疗方法来解决胶质母细胞瘤复发问题
  • 批准号:
    MR/Y008049/1
  • 财政年份:
    2023
  • 资助金额:
    $ 9.5万
  • 项目类别:
    Research Grant

相似国自然基金

Novel-miR-1134调控LHCGR的表达介导拟 穴青蟹卵巢发育的机制研究
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
  • 批准号:
    82304677
  • 批准年份:
    2023
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
  • 批准号:
    82304658
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
novel-miR-59靶向HMGAs介导儿童早衰症细胞衰老的作用及机制研究
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    58 万元
  • 项目类别:
    面上项目
novel_circ_008138/rno-miR-374-3p/SFRP4调控Wnt信号通路参与先天性肛门直肠畸形发生的分子机制研究
  • 批准号:
    82070530
  • 批准年份:
    2020
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目
miRNA-novel-272通过靶向半乳糖凝集素3调控牙鲆肠道上皮细胞炎症反应的机制研究
  • 批准号:
    32002421
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
m6A修饰介导的lncRNA WEE2-AS1转录后novel-pri-miRNA剪切机制在胶质瘤恶性进展中的作用研究
  • 批准号:
  • 批准年份:
    2020
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目
miRNA/novel_167靶向抑制Dmrt1的表达在红鳍东方鲀性别分化过程中的功能研究
  • 批准号:
    31902347
  • 批准年份:
    2019
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Molecular and Cellular Regulation of Uterine Morphogenesis
子宫形态发生的分子和细胞调节
  • 批准号:
    10750127
  • 财政年份:
    2024
  • 资助金额:
    $ 9.5万
  • 项目类别:
'Smart Ventilation' - Novel Real-Time Biosensors and Artificial Intelligence for Optimized Mechanical Ventilation in Human Lungs
“智能通气”——新型实时生物传感器和人工智能,用于优化人肺机械通气
  • 批准号:
    489877
  • 财政年份:
    2023
  • 资助金额:
    $ 9.5万
  • 项目类别:
    Operating Grants
Developing novel technologies to analyse cellular differentiation processes during embryonic development in vivo and ex vivo
开发新技术来分析体内和离体胚胎发育过程中的细胞分化过程
  • 批准号:
    2888341
  • 财政年份:
    2023
  • 资助金额:
    $ 9.5万
  • 项目类别:
    Studentship
Project 2: Ex Vivo Modeling and Analysis of Gastric Precancerous Lesions
项目2:胃癌前病变的离体建模与分析
  • 批准号:
    10715763
  • 财政年份:
    2023
  • 资助金额:
    $ 9.5万
  • 项目类别:
High density chronic optogenetic interface for primate brains
灵长类大脑的高密度慢性光遗传学接口
  • 批准号:
    10706899
  • 财政年份:
    2023
  • 资助金额:
    $ 9.5万
  • 项目类别:
Ex vivo whole ovary culture system for screening gonadotoxicity during drug development
用于在药物开发过程中筛选性腺毒性的离体全卵巢培养系统
  • 批准号:
    10823136
  • 财政年份:
    2023
  • 资助金额:
    $ 9.5万
  • 项目类别:
Cell-free hemoglobin-oxidized LDL-LOX-1 axis and microvascular hyperpermeability during sepsis
脓毒症期间无细胞血红蛋白氧化的 LDL-LOX-1 轴和微血管通透性过高
  • 批准号:
    10739620
  • 财政年份:
    2023
  • 资助金额:
    $ 9.5万
  • 项目类别:
Identification of the molecular and cellular mechanisms driving cardiac fibrosis: A novel ex-vivo approach to target identification and validation
驱动心脏纤维化的分子和细胞机制的鉴定:一种新颖的体外靶标鉴定和验证方法
  • 批准号:
    NC/X001733/1
  • 财政年份:
    2023
  • 资助金额:
    $ 9.5万
  • 项目类别:
    Training Grant
A Modality-Agnostic Potency Assay Enabling Both Ex Vivo and In Vivo Genome Editing Therapeutics for Sickle Cell Disease
一种与模态无关的效力测定,可实现镰状细胞病的体外和体内基因组编辑治疗
  • 批准号:
    10668694
  • 财政年份:
    2023
  • 资助金额:
    $ 9.5万
  • 项目类别:
Targeting Immune-Responsive Gene 1 (Irg1) and Itaconate for Cardioprotection of the Donor Heart for Transplantation
靶向免疫反应基因 1 (Irg1) 和衣康酸对移植供体心脏进行心脏保护
  • 批准号:
    10895712
  • 财政年份:
    2023
  • 资助金额:
    $ 9.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了